Scarica l'app Stockscreener
12.20
2.22%
0.265
Dopo l'orario di chiusura:
12.25
0.05
+0.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Precedente Chiudi:
$11.94
Aprire:
$12
Volume 24 ore:
2.97M
Relative Volume:
1.13
Capitalizzazione di mercato:
$2.12B
Reddito:
$61.10M
Utile/perdita netta:
$-138.36M
Rapporto P/E:
-9.037
EPS:
-1.35
Flusso di cassa netto:
$-90.59M
1 W Prestazione:
+2.18%
1M Prestazione:
-1.89%
6M Prestazione:
+70.15%
1 anno Prestazione:
+6.36%
Intervallo 1D:
$11.84
$12.33
Intervallo di 1 settimana:
$11.10
$12.33
Portata 52W:
$5.80
$13.85
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Nome
Ocular Therapeutix Inc
Settore
Industria
Telefono
781-357-4000
Indirizzo
15 CROSBY DRIVE, BEDFORD, MA
Confronta OCUL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
12.20 | 2.38B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-15 | Iniziato | Chardan Capital Markets | Buy |
| 2025-04-08 | Iniziato | William Blair | Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-11 | Iniziato | Needham | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-20 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-02-09 | Iniziato | BofA Securities | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-10 | Ripresa | Berenberg | Buy |
| 2021-08-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-11-13 | Reiterato | Raymond James | Strong Buy |
| 2020-08-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-03 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-05-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Iniziato | Raymond James | Strong Buy |
| 2018-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-07-12 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-08-11 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Analyzing drawdowns of Ocular Therapeutix Inc. with statistical toolsTrade Analysis Summary & Short-Term High Return Strategies - newser.com
Why Ocular Therapeutix Inc. (0OT) stock is trending on social media2025 Year in Review & Expert Verified Movement Alerts - newser.com
What momentum shifts mean for Ocular Therapeutix Inc.Weekly Trade Analysis & Safe Swing Trade Setups - newser.com
Published on: 2025-10-15 11:24:43 - newser.com
How institutional ownership impacts Ocular Therapeutix Inc. stockWeekly Trend Summary & Target Return Focused Picks - newser.com
Why analysts upgrade Ocular Therapeutix Inc. stock2025 Breakouts & Breakdowns & Low Risk Investment Opportunities - newser.com
Can Ocular Therapeutix Inc. stock maintain growth trajectoryJuly 2025 Volume & Expert Approved Momentum Ideas - newser.com
Is Ocular Therapeutix Inc. stock a buy in volatile marketsStock Surge & Free Safe Entry Trade Signal Reports - newser.com
Ocular Therapeutix (OCUL) Falls Hard on $475-Million Share Sale - MSN
Is Ocular Therapeutix Inc. stock oversold or undervaluedEntry Point & Real-Time Market Trend Scan - newser.com
Exit strategy if you’re trapped in Ocular Therapeutix Inc.2025 EndofYear Setup & Free Expert Verified Stock Movement Alerts - newser.com
How to recover losses in Ocular Therapeutix Inc. stockEarnings Trend Report & Daily Profit Maximizing Tips - newser.com
Using Ichimoku Cloud for Ocular Therapeutix Inc. technicalsGap Down & Fast Moving Stock Watchlists - newser.com
Ocular Therapeutix Inc. stock trendline breakdownWall Street Watch & Expert Curated Trade Ideas - newser.com
Real time pattern detection on Ocular Therapeutix Inc. stockWeekly Profit Recap & Reliable Volume Spike Alerts - newser.com
How risky is Ocular Therapeutix Inc. (0OT) stock compared to peersRecession Risk & Weekly Chart Analysis and Guides - newser.com
Ocular Therapeutix (OCUL): Assessing Valuation After Clinical Progress, Analyst Upgrades, and Major Fundraising - Sahm
Todd Anderman Sells 11,132 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
FY2025 EPS Estimate for Ocular Therapeutix Raised by Analyst - MarketBeat
Ocular Therapeutix chief legal officer Anderman sells $137k in stock - Investing.com Canada
How to track smart money flows in Ocular Therapeutix Inc.July 2025 Fed Impact & AI Driven Price Forecasts - newser.com
Using AI based signals to follow Ocular Therapeutix Inc.Earnings Recap Summary & Safe Investment Capital Preservation Plans - newser.com
Ocular Therapeutix (NASDAQ:OCUL) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
What machine learning models say about Ocular Therapeutix Inc.IPO Watch & Trade Opportunity Analysis - newser.com
Published on: 2025-10-10 03:24:04 - newser.com
Using R and stats models for Ocular Therapeutix Inc. forecastingMarket Risk Analysis & Smart Allocation Stock Reports - newser.com
Is Ocular Therapeutix Inc. (0OT) stock considered safe haven2025 Market Outlook & Reliable Breakout Forecasts - newser.com
Price action breakdown for Ocular Therapeutix Inc.2025 Retail Activity & Weekly Stock Breakout Alerts - newser.com
WilmerHale Advised Ocular Therapeutix™ in $475 Million Underwritten Offering - WilmerHale
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL): HC Wainwright & Co. Raises Price Targ - GuruFocus
Piper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21 - Yahoo Finance
Ocular Therapeutix, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewswire
1-Year HELIOS Phase 1 Results: Ocular Therapeutix Presents OTX-TKI Data at Oct 2025 Scientific Conferences - Stock Titan
Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $106,472.59 in Stock - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Insider Jeffrey Heier Sells 10,502 Shares - MarketBeat
What analysts say about Ocular Therapeutix Inc stockGap Up/Gap Down Analysis & Free Rapid Wealth Building - earlytimes.in
Ocular Therapeutix (OCUL) Is Down 8.9% After $475M Equity Raise to Fund Axpaxli Trials — Has the Bull Case Changed? - Sahm
Ocular Therapeutix Inc Azioni (OCUL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):